Literature DB >> 17897307

Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study.

Yesim Dargaud1, Rodger Luddington, Elaine Gray, Claude Negrier, Thomas Lecompte, Sirak Petros, John Hogwood, Jean-Claude Bordet, Veronique Regnault, Annelie Siegemund, Trevor Baglin.   

Abstract

Calibrated automated thrombography (CAT) enables continuous measurement of thrombin generation (TG). Initial clinical studies using the CAT method showed large variability of normal values, indicating the necessity for a standardized CAT protocol. This international study assessed the intra- and inter-assay imprecision of CAT as well as the inter-centre variability of results in five European centres using locally available reagents and conditions (study 1) and a standardized protocol in which results were normalized (study 2). Samples with and without corn trypsin inhibitor from six healthy volunteers, two haemophilia patients and one protein C deficient patient were assayed. Study 1 confirmed that the use of different sources and concentrations of tissue factor (TF) and different phospholipid (PL) mixtures produced large variability in results. The second study demonstrated that, using the same source and concentration of TF, PL and the same test procedure, this variability could be significantly reduced. Normalization of results improved the inter-centre variability. The benefit of contact factor inhibition prior to TG measurement was confirmed. These results demonstrated that standardization of CAT reduces the variability of results to acceptable limits. Standardization and normalization should be considered in future clinical studies which apply TG testing to clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897307     DOI: 10.1111/j.1365-2141.2007.06785.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.

Authors:  Y Dargaud; A S Wolberg; E Gray; C Negrier; H C Hemker
Journal:  J Thromb Haemost       Date:  2017-06-28       Impact factor: 5.824

2.  Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System.

Authors:  Ute Gravemann; Manuela Kusch; Herbert Koenig; Harald Mohr; Thomas H Mueller
Journal:  Transfus Med Hemother       Date:  2009-03-04       Impact factor: 3.747

Review 3.  Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.

Authors:  Denis Wahl; Aurélie Membre; Christine Perret-Guillaume; Véronique Regnault; Thomas Lecompte
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

4.  Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram.

Authors:  Kellie R Machlus; Emily A Colby; Jogin R Wu; Gary G Koch; Nigel S Key; Alisa S Wolberg
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

Review 5.  Global assays of hemostasis.

Authors:  Kathleen E Brummel-Ziedins; Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 6.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

7.  Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.

Authors:  P L Lutsey; A R Folsom; S R Heckbert; M Cushman
Journal:  J Thromb Haemost       Date:  2009-07-28       Impact factor: 5.824

8.  Thrombin generation in the Glasgow Myocardial Infarction Study.

Authors:  Machiel Smid; Arne W J H Dielis; Henri M H Spronk; Ann Rumley; Rene van Oerle; Mark Woodward; Hugo ten Cate; Gordon Lowe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959

10.  Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system.

Authors:  Christian Pfrepper; Michael Metze; Annelie Siegemund; Tristan Klöter; Thomas Siegemund; Sirak Petros
Journal:  Res Pract Thromb Haemost       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.